SCHEMBL4594400

SCHEMBL4594400

COc1ccccc1-c1ccc(NCC(C)(C)NCC(=O)N2CCCC2C#N)nc1

nearest known ligand 0.70

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 19/20 0.70
DPP7 Q9UHL4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL665743 1.00 DPP4 (0.70) DPP4DPP7
SCHEMBL663044 0.90 DPP4 (0.67) DPP4DPP7
SCHEMBL4594238 0.90 DPP4 (0.67) DPP4DPP7
SCHEMBL666507 0.89 DPP4 (0.76) DPP4DPP7
SCHEMBL666256 0.88 DPP4 (0.72) DPP4DPP7
SCHEMBL1435960 0.88 DPP4 (0.72) DPP4DPP7
SCHEMBL664934 0.88 DPP4 (0.69) DPP4DPP7
SCHEMBL1436301 0.88 DPP4 (0.69) DPP4DPP7
SCHEMBL4594545 0.87 DPP4 (0.67) DPP4DPP7
SCHEMBL663965 0.87 DPP4 (0.67) DPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917001-A2 PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR F.HOFFMANN-LA ROCHE AG (CH) 2008-05-07 EP disclosed
US-20070259925-A1 DPP IV INHIBITORS BOEHRINGER MARKUS 2007-11-08 US disclosed
WO-2007017423-A2 PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR F. HOFFMANN-LA ROCHE AG (CH) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259925-A1 DPP IV INHIBITORS DPP4, DPP3, DPP7 DPP4 1/4885DPP7 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.